Phase-0/microdosing studies using PET, AMS, and LC-MS/MS: a range of study methodologies and conduct considerations. Accelerating development of novel pharmaceuticals through safe testing in humans – a practical guide

References

• Munos B. Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov. 2009 Dec;8(12):959–968.
   PubMed Web of Science ®Google Scholar
• Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rssev Drug Discov. 2010 Mar;9(3):203–214.
   PubMed Web of Science ®Google Scholar
• FDA. Innovation or stagnation: challenge and opportunity on the critical path to new medical products. http://wwwfdagov/oc/initiatives/criticalpath/whitepaperhtml 2004.
   Google Scholar
• Burt T, Dhillon S. Pharmacogenomics in early-phase clinical development. Pharmacogenomics. 2013 Jul;14(9):1085–1097.
   PubMed Web of Science ®Google Scholar
• IOM. evolution of translational omics: lessons learned and the path forward. Washington (DC): The National Academies Press; 2012.
   Google Scholar
• DiMasi JA, Feldman L, Seckler A, et al. Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther. 2010 Mar;87(3):272–277.
   PubMed Web of Science ®Google Scholar
• Coller BS, Califf RM. Traversing the valley of death: a guide to assessing prospects for translational success. Sci Transl Med. 2009 Dec 9;1(10):10cm9.
   PubMed Web of Science ®Google Scholar
• Eapen ZJ, Vavalle JP, Granger CB, et al. Rescuing clinical trials in the United States and beyond: a call for action. Am Heart J. 2013 Jun;165(6):837–847.
   PubMed Web of Science ®Google Scholar
• Burt T, Nandal S. Pharmacometabolomics in early-phase clinical development. Clin Transl Sci. 2016 Apr 29;9:128–138.
   PubMed Web of Science ®Google Scholar
• FDA. Guidance for industry, investigators, and reviewers exploratory IND studies. 2006. Available from: http://wwwfdagov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM078933pdf
   Google Scholar
• ICH. Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals M3(R2). In: International conference on harmonization of technical requirements for registration of pharmaceuticals for human use. Geneve: ICH Secretariat; 2009. p. 8–16.
   Google Scholar
• EMEA. Position paper on non-clinical safety studies to support clinical trials with a single microdose. Position paper CPMP/SWP/2599. 2004. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000400.jsp
   Google Scholar
• MHLW. Guidance. Microdose clinical studies. Tokyo: Ministry of Health LaW. Pharmaceutical and Medical Safety Bureau ed. 2008.
   Google Scholar
• Burt T, Yoshida K, Lappin G, et al. Microdosing and other phase-0 clinical trials: facilitating translation in drug development. Clin Transl Sci. 2016 Feb 26;9(2):74–88.
   PubMed Web of Science ®Google Scholar
• Lappin G, Garner RC. Big physics, small doses: the use of AMS and PET in human microdosing of development drugs. Nat Rev Drug Discov. 2003 Mar;2(3):233–240.
   PubMed Web of Science ®Google Scholar
• Sugiyama Y. Effective use of microdosing and positron emission tomography (PET) studies on new drug discovery and development. Drug Metab Pharmacokinet. 2009;24(2):127–129.
   PubMed Web of Science ®Google Scholar
• Bergström M, Grahnén A, Långström B. Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development. Eur J Clin Pharmacol. 2003 Sep;59(5–6):357–366.
   PubMed Web of Science ®Google Scholar
• Sugiyama Y, Yamashita S. Impact of microdosing clinical study – why necessary and how useful? Adv Drug Deliv Rev. 2011 Jun 19;63(7):494–502.
   PubMed Web of Science ®Google Scholar
• Yamane N, Igarashi A, Kusama M, et al. Cost-effectiveness analysis of microdose clinical trials in drug development. Drug Metab Pharmacokinet. 2013;28(3):187–195.
   PubMed Web of Science ®Google Scholar
• Rowland M, Benet LZ. Lead PK commentary: predicting human pharmacokinetics. J Pharm Sci. 2011 May 31;100:4047–4049.
   PubMed Web of Science ®Google Scholar
• Vuong LT, Song Q, Lee HJ, et al. Opportunities in low-level radiocarbon microtracing: applications and new technology. Future Science OA. 2015 [2016 Mar 1];2(1):1–22.
   Web of Science ®Google Scholar
• Wagner CC, Müller M, Lappin G, et al. Positron emission tomography for use in microdosing studies. Curr Opin Drug Discov Devel. 2008 Jan;11(1):104–110.
   PubMed Web of Science ®Google Scholar
• Maeda K, Sugiyama Y. Novel strategies for microdose studies using non-radiolabeled compounds. Adv Drug Deliv Rev. 2011;63:532–538.
   PubMed Web of Science ®Google Scholar
• Ieiri I, Fukae M, Maeda K, et al. Pharmacogenomic/pharmacokinetic assessment of a four-probe cocktail for CYPs and OATPs following oral microdosing. Int J Clin Pharmacol Ther. 2012 Oct;50(10):689–700.
   PubMed Web of Science ®Google Scholar
• Yoshida K, Maeda K, Sugiyama Y. Hepatic and intestinal drug transporters: prediction of pharmacokinetic effects caused by drug-drug interactions and genetic polymorphisms. Annu Rev Pharmacol Toxicol. 2013;53:581–612.
   PubMed Web of Science ®Google Scholar
• Vuong LT, Blood AB, Vogel JS, et al. Applications of accelerator MS in pediatric drug evaluation. Bioanalysis. 2012 Aug;4(15):1871–1882.
   PubMed Web of Science ®Google Scholar
• Vogel JS, Lohstroh P, Keck B, et al. Quantitative drug metabolism with accelerator mass spectrometry. In: Lee MS, Zhu M, editors. Mass spectrometry in drug metabolism and disposition: basic principles and applications. Hoboken, NJ: Wiley; 2011. p. 525–566.
   Google Scholar
• Wagner CC, Langer O. Approaches using molecular imaging technology – use of PET in clinical microdose studies. Adv Drug Deliv Rev. 2011 Jun 19;63(7):539–546.
   PubMed Web of Science ®Google Scholar
• Burt T, Rouse DC, Lee K, et al. Intraarterial microdosing: a novel drug development approach, proof-of-concept PET study in rats. J Nucl Med. 2015 Nov;56(11):1793–1799.
   PubMed Web of Science ®Google Scholar
• Vlaming M, van Duijn E, Dillingh MR, et al. Microdosing of a carbon-14 labeled protein in healthy volunteers accurately predicts its pharmacokinetics at therapeutic dosages. Clin Pharmacol Ther. 2015 Aug;98(2):196–204.
   PubMed Web of Science ®Google Scholar
• Wagner CC, Simpson M, Zeitlinger M, et al. A combined accelerator mass spectrometry-positron emission tomography human microdose study with 14C- and 11C-labelled verapamil. Clin Pharmacokinet. 2010 Dec 13;50(2):111–120.
   Web of Science ®Google Scholar
• IOM. Improving the utility and translation of animal models for nervous system disorders: workshop summary. Washington (DC): The National Academies Press; 2013.
   Google Scholar
• van der Worp HB, Howells DW, Sena ES, et al. Can animal models of disease reliably inform human studies? PLoS Med. 2010 Mar;7(3):e1000245.
   PubMed Web of Science ®Google Scholar
• Seymour M. The best model for humans is human – how to accelerate early drug development safely. Altern Lab Anim. 2009 Sep;37(Suppl 1):61–65.
   PubMed Web of Science ®Google Scholar
• Musther H, Olivares-Morales A, Hatley OJ, et al. Animal versus human oral drug bioavailability: do they correlate? Eur J Pharm Sci. 2014;57:280–291.
   PubMed Web of Science ®Google Scholar
• Perel P, Roberts I, Sena E, et al. Comparison of treatment effects between animal experiments and clinical trials: systematic review. BMJ. 2007 Jan 27;334(7586):197.
   PubMed Web of Science ®Google Scholar
• Hackam DG, Redelmeier DA. Translation of research evidence from animals to humans. JAMA. 2006 Oct 11;296(14):1731–1732.
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ. In vitro prediction of clinical drug interactions with CYP3A substrates: we are not there yet. Clin Pharmacol Ther. 2014 Feb;95(2):133–135.
   PubMed Web of Science ®Google Scholar
• Lappin G, Noveck R, Burt T. Microdosing and drug development: past, present and future. Expert Opin Drug Metab Toxicol. 2013 Jul;9(7):817–834.
   PubMed Web of Science ®Google Scholar
• EUMAPP. European Microdosing AMS Partnership Programme: outcomes from EUMAPP - a study comparing in vitro, in silico, microdose and pharmacologic dose pharmacokinetics. 2009. Available from: www.EUMAPP.com
   Google Scholar
• Lappin G, Kuhnz W, Jochemsen R, et al. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. Clin Pharmacol Ther. 2006 Sep;80(3):203–215.
   PubMed Web of Science ®Google Scholar
• Bauer M, Wagner CC, Langer O. Microdosing studies in humans: the role of positron emission tomography. Drugs in R & D. 2008;9(2):73–81.
   Google Scholar
• Henderson PT, Li T, He M, et al. A microdosing approach for characterizing formation and repair of carboplatin-DNA monoadducts and chemoresistance. Int J Cancer. 2011 Sep 15;129(6):1425–1434.
   PubMed Web of Science ®Google Scholar
• Vuong LT, Ruckle JL, Blood AB, et al. Use of accelerator mass spectrometry to measure the pharmacokinetics and peripheral blood mononuclear cell concentrations of zidovudine. J Pharm Sci. 2008 Sep 13;97(7):2833–2843.
   PubMed Web of Science ®Google Scholar
• Bijleveld Y, De Haan T, Toersche J, et al. A simple quantitative method analysing amikacin, gentamicin, and vancomycin levels in human newborn plasma using ion-pair liquid chromatography/tandem mass spectrometry and its applicability to a clinical study. J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Mar 1;951–952:110–118.
   PubMed Web of Science ®Google Scholar
• Yamane N, Tozuka Z, Kusama M, et al. Clinical relevance of liquid chromatography tandem mass spectrometry as an analytical method in microdose clinical studies. Pharm Res. 2011 Aug;28(8):1963–1972.
   PubMed Web of Science ®Google Scholar
• Bergstrom M, Cass LM, Valind S, et al. Deposition and disposition of [11C]zanamivir following administration as an intranasal spray. Evaluation with positron emission tomography. Clin Pharmacokinet. 1999;36(Suppl 1):33–39.
   PubMed Web of Science ®Google Scholar
• Gulyás B, Halldin C, Sóvágó J, et al. Drug distribution in man: a positron emission tomography study after oral administration of the labelled neuroprotective drug vinpocetine. Eur J Nucl Med Mol Imaging. 2002 Aug;29(8):1031–1038.
   PubMed Web of Science ®Google Scholar
• Wilding IR, Bell JA. Improved early clinical development through human microdosing studies. Drug Discov Today. 2005 Jul 1;10(13):890–894.
   PubMed Web of Science ®Google Scholar
• DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003 Mar;22(2):151–185.
   PubMed Web of Science ®Google Scholar
• Rowland M. Microdosing and the 3Rs. In: National centre for the replacement, refinement & reduction of animals in research. Manchester: National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs); 2006.
   Google Scholar
• Heuveling DA, de Bree R, Vugts DJ, et al. Phase 0 microdosing PET study using the human mini antibody F16SIP in head and neck cancer patients. J Nucl Med. 2013 Jan 18;54:397–401.
   PubMed Web of Science ®Google Scholar
• Hillyar CR, Knight JC, Vallis KA, et al. PET and SPECT imaging for the acceleration of anti-cancer drug development. Current Drug Targets. 2015;16(6):582–591.
   PubMed Web of Science ®Google Scholar
• Takano A, Kusuhara H, Suhara T, et al. Evaluation of in vivo P-glycoprotein function at the blood-brain barrier among MDR1 gene polymorphisms by using 11C-verapamil. J Nucl Med. 2006 Sep;47(9):1427–1433.
   PubMed Web of Science ®Google Scholar
• Bauer M, Zeitlinger M, Karch R, et al. Pgp-mediated interaction between (R)-[11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat data. Clin Pharmacol Ther. 2012 Feb;91(2):227–233.
   PubMed Web of Science ®Google Scholar
• Bauer M, Langer O, Dal-Bianco P, et al. A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimer’s disease. Clin Pharmacol Ther. 2006 Sep;80(3):216–227.
   PubMed Web of Science ®Google Scholar
• Waarde A. Measuring receptor occupancy with PET. Curr Pharm Des. 2000 Nov;6(16):1593–1610.
   PubMed Web of Science ®Google Scholar
• Zamuner S, Di Iorio VL, Nyberg J, et al. Adaptive-optimal design in PET occupancy studies. Clin Pharmacol Ther. 2010 May;87(5):563–571.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Fox GB. PET imaging for receptor occupancy: meditations on calculation and simplification. J Biomed Res. 2012 Mar;26(2):69–76.
   PubMedGoogle Scholar
• Benet LZ, Broccatelli F, Oprea TI. BDDCS applied to over 900 drugs. AAPS J. 2011 Dec;13(4):519–547.
   PubMed Web of Science ®Google Scholar
• Nayak TK, Brechbiel MW. Radioimmunoimaging with longer-lived positron-emitting radionuclides: potentials and challenges. Bioconjug Chem. 2009 May 20;20(5):825–841.
   PubMed Web of Science ®Google Scholar
• Lamers RJ, de Jong AF, López-Gutiérrez JM, et al. Iodine-129 microdosing for protein and peptide drug development: erythropoietin as a case study. Bioanalysis. 2013 Jan;5(1):53–63.
   PubMed Web of Science ®Google Scholar
• Van Der Veldt AA, Lubberink M, Mathijssen RH, et al. Toward prediction of efficacy of chemotherapy: a proof of concept study in lung cancer patients using [¹¹C]docetaxel and positron emission tomography. Clin Cancer Res. 2013 Aug 1;19(15):4163–4173.
   PubMed Web of Science ®Google Scholar
• Gunn RN, Summerfield SG, Salinas CA, et al. Combining PET biodistribution and equilibrium dialysis assays to assess the free brain concentration and BBB transport of CNS drugs. J Cereb Blood Flow Metab. 2012 May;32(5):874–883.
   PubMed Web of Science ®Google Scholar
• Schou M, Varnäs K, Lundquist S, et al. Large variation in brain exposure of reference CNS drugs: a PET study in nonhuman primates. Int J Neuropsychopharmacol. 2015 Sep;18(10):pyv036.
   PubMed Web of Science ®Google Scholar
• Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging. 2003 Jul;2(3):131–137.
   PubMedGoogle Scholar
• Barbaras L, Tal I, Palmer MR, et al. Shareware program for nuclear medicine and PET/CT PACS display and processing. AJR Am J Roentgenol. 2007 Jun;188(6):W565–W568.
   PubMed Web of Science ®Google Scholar
• Vogel JS, Keating GA 2nd, Buchholz BA. Protein binding of isofluorophate in vivo after coexposure to multiple chemicals. Environ Health Perspect. 2002 Dec;110(Suppl 6):1031–1036.
   PubMed Web of Science ®Google Scholar
• Turteltaub KW, Vogel JS. Bioanalytical applications of accelerator mass spectrometry for pharmaceutical research. Curr Pharm Des. 2000 Jul;6(10):991–1007.
   PubMed Web of Science ®Google Scholar
• Arjomand A. Accelerator mass spectrometry-enabled studies: current status and future prospects. Bioanalysis. 2010 Mar;2(3):519–541.
   PubMed Web of Science ®Google Scholar
• Yokel RA, McNamara PJ. Aluminium toxicokinetics: an updated minireview. Pharmacol Toxicol. 2001 Apr;88(4):159–167.
   PubMedGoogle Scholar
• Vogel JS, Love AH. Quantitating isotopic molecular labels with accelerator mass spectrometry. Methods Enzymol. 2005;402:402–422.
   PubMed Web of Science ®Google Scholar
• Turteltaub KW, Felton JS, Gledhill BL, et al. Accelerator mass spectrometry in biomedical dosimetry: relationship between low-level exposure and covalent binding of heterocyclic amine carcinogens to DNA. Proc Natl Acad Sci U S A. 1990 Jul;87(14):5288–5292.
   PubMed Web of Science ®Google Scholar
• Vogel JS, Turteltaub KW, Finkel R, et al. Accelerator mass spectrometry. Anal Chem. 1995 Jun 1;67(11):353A–359A.
   PubMed Web of Science ®Google Scholar
• Gordi T, Baillie R, Vuong Le T, et al. Pharmacokinetic analysis of 14C-ursodiol in newborn infants using accelerator mass spectrometry. J Clin Pharmacol. 2014 Sep;54(9):1031–1037.
   PubMed Web of Science ®Google Scholar
• Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res B Dev Reprod Toxicol. 2009 Aug;86(4):328–344.
   PubMed Web of Science ®Google Scholar
• Maxwell BD, Cao K, Bonacorsi S, et al. The synthesis of a carbon-14 labeled pegylated Adnectin™ for placental transfer studies in guinea pigs. J Labelled Comp Radiopharm. 2013 Jul–Aug;56(9–10):492–494.
   PubMed Web of Science ®Google Scholar
• Ings R. Microdosing: a valuable tool for accelerating drug development and the role of bioanalytical methods in meeting the challenge. Bioanalysis. 2009;1(17):1293–1305.
   PubMed Web of Science ®Google Scholar
• Turteltaub KW, Dingley KH. Application of accelerated mass spectrometry (AMS) in DNA adduct quantification and identification. Toxicol Lett. 1998 Dec 28;102–103:435–439.
   PubMed Web of Science ®Google Scholar
• Ognibene TJ, Bench G, Vogel JS, et al. A high-throughput method for the conversion of CO2 obtained from biochemical samples to graphite in septa-sealed vials for quantification of 14C via accelerator mass spectrometry. Anal Chem. 2003 May 1;75(9):2192–2196.
   PubMed Web of Science ®Google Scholar
• Burhenne J, Halama B, Maurer M, et al. Quantification of femtomolar concentrations of the CYP3A substrate midazolam and its main metabolite 1’-hydroxymidazolam in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometry. Anal Bioanal Chem. 2012 Mar;402(7):2439–2450.
   PubMed Web of Science ®Google Scholar
• Yamane N, Tozuka Z, Sugiyama Y, et al. Microdose clinical trial: quantitative determination of fexofenadine in human plasma using liquid chromatography/electrospray ionization tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Oct 15; 858(1–2):118–128.
   PubMed Web of Science ®Google Scholar
• Balani SK, Nagaraja NV, Qian MG, et al. Evaluation of microdosing to assess pharmacokinetic linearity in rats using liquid chromatography-tandem mass spectrometry. Drug Metab Dispos. 2006 Mar;34(3):384–388.
   PubMed Web of Science ®Google Scholar
• Miyaji Y, Ishizuka T, Kawai K, et al. Use of an intravenous microdose of 14C-labeled drug and accelerator mass spectrometry to measure absolute oral bioavailability in dogs; cross-comparison of assay methods by accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry. Drug Metab Pharmacokinet. 2009;24(2):130–138.
   PubMed Web of Science ®Google Scholar
• Sun L, Li H, Willson K, et al. Ultrasensitive liquid chromatography-tandem mass spectrometric methodologies for quantification of five HIV-1 integrase inhibitors in plasma for a microdose clinical trial. Anal Chem. 2012 Oct 16;84(20):8614–8621.
   PubMed Web of Science ®Google Scholar
• Phillips LR, Hill KD, Majerova E. Liquid chromatographic determination of NSC 737664 (ABT-888: an inhibitor of poly(ADP-ribose) polymerase (PARP)) in plasma and urine in a phase 0 clinical trial. J Liq Chromatogr Relat Technol. 2009 Jan;32(2):261–272.
   PubMed Web of Science ®Google Scholar
• Gu H, Wang J, Aubry A-F, et al. Calculation and mitigation of isotopic interferences in liquid chromatography-mass spectrometry/mass spectrometry assays and its application in supporting microdose absolute bioavailability studies. Anal Chem. 2012 Jun 5;84(11):4844–4850.
   PubMed Web of Science ®Google Scholar
• Sarapa N, Hsyu P-H, Lappin G, et al. The application of accelerator mass spectrometry to absolute bioavailability studies in humans: simultaneous administration of an intravenous microdose of 14C-nelfinavir mesylate solution and oral nelfinavir to healthy volunteers. J Clin Pharmacol. 2005 Oct;45(10):1198–1205.
   PubMed Web of Science ®Google Scholar
• Madan A, O’Brien Z, Wen J, et al. A pharmacokinetic evaluation of five H1 antagonists after an oral and intravenous microdose to human subjects. Br J Clin Pharmacol. 2009;67(3):288–298.
   PubMed Web of Science ®Google Scholar
• Minamide Y, Osawa Y, Nishida H, et al. A highly sensitive LC-MS/MS method capable of simultaneously quantitating celiprolol and atenolol in human plasma for a cassette cold-microdosing study. J Sep Sci. 2011 Jul;34(13):1590–1598.
   PubMed Web of Science ®Google Scholar
• Maeda K, Ikeda Y, Fujita T, et al. Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study. Clin Pharmacol Ther. 2011 Oct;90(4):575–581.
   PubMed Web of Science ®Google Scholar
• Jadhav AP, Jovin TG. Intra-arterial reperfusion strategies in acute ischemic stroke. J Neurointerv Surg. 2013 May;5(Suppl 1):i66–i69.
   PubMed Web of Science ®Google Scholar
• Gowdra Halappa V, Corona-Villalobos CP, Bonekamp S, et al. Neuroendocrine liver metastasis treated by using intraarterial therapy: volumetric functional imaging biomarkers of early tumor response and survival. Radiology. 2013 Feb;266(2):502–513.
   PubMed Web of Science ®Google Scholar
• Song MJ, Bae SH, Yoo le R, et al. Predictive value of (1)(8)F-fluorodeoxyglucose PET/CT for transarterial chemolipiodolization of hepatocellular carcinoma. World J Gastroenterol. 2012 Jul 7;18(25):3215–3222.
   PubMed Web of Science ®Google Scholar
• Liu F, Tang Y, Sun J, et al. Regional intra-arterial vs. systemic chemotherapy for advanced pancreatic cancer: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2012;7(7):e40847.
   PubMed Web of Science ®Google Scholar
• Memon MZ, Natarajan SK, Sharma J, et al. Safety and feasibility of intraarterial eptifibatide as a revascularization tool in acute ischemic stroke. J Neurosurg. 2011 Apr;114(4):1008–1013.
   PubMed Web of Science ®Google Scholar
• Croft M, Keely B, Morris I, et al. Predicting drug candidate victims of drug-drug interactions, using microdosing. Clin Pharmacokinet. 2012 Apr 1;51(4):237–246.
   PubMed Web of Science ®Google Scholar
• Ieiri I, Tsunemitsu S, Maeda K, et al. Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs. J Clin Pharmacol. 2013 Jun;53(6):654–661.
   PubMed Web of Science ®Google Scholar
• Garner RC, Lappin G. The phase 0 microdosing concept. Br J Clin Pharmacol. 2006 Apr;61(4):367–370.
   PubMed Web of Science ®Google Scholar
• De Vries R, Smit JW, Hellemans P, et al. Stable isotope-intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adults. Br J Clin Pharmacol. 2016;81:235–245.
   PubMed Web of Science ®Google Scholar
• Ieiri I, Nishimura C, Maeda K, et al. Pharmacokinetic and pharmacogenomic profiles of telmisartan after the oral microdose and therapeutic dose. Pharmacogenet Genomics. 2011 Aug;21(8):495–505.
   PubMed Web of Science ®Google Scholar
• Gueorguieva I, Ogungbenro K, Graham G, et al. A program for individual and population optimal design for univariate and multivariate response pharmacokinetic-pharmacodynamic models. Comput Methods Programs Biomed. 2007 Apr;86(1):51–61.
   PubMed Web of Science ®Google Scholar
• Kimmelman J Ethics at phase 0: clarifying the issues. J Law Med Ethics. 2007 Winter;35(4):514, 727–733.
   Web of Science ®Google Scholar
• Kurihara C. Ethical, legal, and social implications (ELSI) of microdose clinical trials. Adv Drug Deliv Rev. 2011 Jun 19;63(7):503–510.
   PubMed Web of Science ®Google Scholar
• Roth-Cline M, Nelson RM. Microdosing studies in children: a US regulatory perspective. Clin Pharmacol Ther. 2015 Sep;98(3):232–233.
   PubMed Web of Science ®Google Scholar
• Roth-Cline M, Nelson RM. Ethical considerations in conducting pediatric and neonatal research in clinical pharmacology. Curr Pharm Des. 2015;21(39):5619–5635.
   PubMed Web of Science ®Google Scholar
• NIH. Clinicaltrials.gov. 2016 [cited 2014 Feb 11]. Available from: http://clinicaltrials.gov/ct2/home
   Google Scholar
• FDA. Section 801 of the Food and Drug Administration Amendments Act. Title VIII - Clinical Trial Databases. Washington (DC): FDA; 2007.
   Google Scholar
• Garner CR, Park KB, French NS, et al. Observational infant exploratory [(14)C]-paracetamol pharmacokinetic microdose/therapeutic dose study with accelerator mass spectrometry bioanalysis. Br J Clin Pharmacol. 2015 Jul;80(1):157–167.
   PubMed Web of Science ®Google Scholar
• Harrison A, Gardner I, Hay T, et al. Case studies addressing human pharmacokinetic uncertainty using a combination of pharmacokinetic simulation and alternative first in human paradigms. Xenobiotica. 2012 Jan;42(1):57–74.
   PubMed Web of Science ®Google Scholar
• Ostenfeld T, Beaumont C, Bullman J, et al. Human microdose evaluation of the novel EP1 receptor antagonist GSK269984A. Br J Clin Pharmacol. 2012 Dec;74(6):1033–1044.
   PubMed Web of Science ®Google Scholar
• Bosgra S, Vlaming ML, Vaes WH. To apply microdosing or not? Recommendations to single out compounds with non-linear pharmacokinetics. Clin Pharmacokinet. 2016 Jan;55(1):1–15.
   PubMed Web of Science ®Google Scholar